Synapse - Works

Results (5608)

Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC)

Meeting Abstract

Choueiri, T. K.; Plimack, E. R.; Powles, T.; Voss, M. H.; Gurney, H.; Silverman, R. K.; Perini, R. F.; Rodriguez-Lopez, K.; Rini, B. I.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor

Meeting Abstract

Choueiri, T. K.; Albiges, L.; Hammers, H. J.; McKay, R. R.; Heng, D. Y. C.; Beckermann, K.; Kasturi, V.; Motzer, R. J.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Blood biomarkers and association with clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC): Prespecified longitudinal analysis from the ACIS study of apalutamide (APA) or placebo combined with abiraterone acetate plus prednisone (AAP)

Meeting Abstract

Efstathiou, E.; Attard, G.; Lucas, J.; Thomas, S.; Gormley, M.; Aguilar-Bonavides, C.; Flaig, T. W.; Franke, F.; Goodman, O. B.; Oudard, S.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Human epidermal growth factor receptor 2 (HER2) and fibroblast growth factor receptor 3 (FGFR3) mutations to reveal biological pathways in urothelial carcinoma

Meeting Abstract

Chu, C. E.; De Jesus Escano, M.; Yip, W.; Jiang, S.; Iyer, G.; Al-Ahmadie, H. A.; Goh, A. C.; Dalbagni, G.; Bochner, B. H.; Solit, D. B.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations

Meeting Abstract

Chi, K. N.; Rathkopf, D. E.; Smith, M. R.; Efstathiou, E.; Attard, G.; Olmos, D.; Lee, J. Y.; Small, E. J.; Gomes, A. J.; Roubaud, G.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Health-related quality of life (HRQoL) in previously untreated patients with advanced renal cell carcinoma (aRCC): CheckMate 9ER updated results

Meeting Abstract

Cella, D.; Motzer, R. J.; Blum, S. I.; Ejzykowicz, F.; Hamilton, M.; Wallace, J.; Zhang, J.; Simsek, B.; Ivanescu, C.; Choueiri, T. K.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Health-related quality of life (HRQoL) in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214: Five-year follow-up results

Meeting Abstract

Cella, D.; Choueiri, T. K.; Hamilton, M.; Ejzykowicz, F.; Blum, S. I.; Ivanescu, C.; Motzer, R. J.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Phase 2 trial of immunotherapy in tumors with CDK12 inactivation (IMPACT): Results from cohort A of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) receiving dual immune checkpoint inhibition (ICI)

Meeting Abstract

Alva, A. S.; Li, J.; Chou, J.; Reimers, M. A.; McKay, R. R.; Zhang, J.; Daignault-Newton, S.; Palmbos, P. L.; Reichert, Z. R.; Cieslik, M.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Distinct differences in genomic profile of gastric and gastroesophageal junction adenocarcinoma

Meeting Abstract

Nakauchi, M.; Walch, H. S.; Chatila, W. K.; Tran, T.; Vos, E. L.; Sihag, S.; Tang, L. H.; Coit, D. G.; Stadler, Z. K.; Janjigian, Y. Y.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Patient-reported outcomes: What really matters to patients? – Authors' reply

Correspondence

Cella, D.; Choueiri, T.K.; Motzer, R. J.
Lancet Oncology (2022)

Fulltext@MSK | Save